MANKIND
Invest Now
Start SIP in
MANKIND
Performance
- Low
- ₹2,300
- High
- ₹2,358
- 52 Week Low
- ₹1,901
- 52 Week High
- ₹3,055
- Open Price₹2,350
- Previous Close₹2,358
- Volume180,419
Investment Returns
- Over 1 Month -9.62%
- Over 3 Month + 8.36%
- Over 6 Month -17.13%
- Over 1 Year + 3.62%
Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!
Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 48.2
- PEG Ratio
- 13.1
- Market Cap Cr
- 95,968
- P/B Ratio
- 9.1
- Average True Range
- 57.06
- EPS
- 48.13
- Dividend Yield
- 0
- MACD Signal
- -26.52
- RSI
- 35.72
- MFI
- 49.61
Mankind Pharma Financials
Mankind Pharma Technicals
EMA & SMA
Current Price
₹2,325.20
-33.1
(-1.4%)

-
- Bearish Moving Average 16
-
- Bullish Moving Average 0
- 20 Day
- ₹2,391.38
- 50 Day
- ₹2,422.41
- 100 Day
- ₹2,445.09
- 200 Day
- ₹2,428.92
Resistance and Support
2327.8
- R3 2,413.80
- R2 2,386.00
- R1 2,355.60
- S1 2,297.40
- S2 2,269.60
- S3 2,239.20
Mankind Pharma Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2025-05-21 | Audited Results | |
2025-01-23 | Quarterly Results | |
2024-11-05 | Quarterly Results | |
2024-07-31 | Quarterly Results | |
2024-05-15 | Audited Results & Others | To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. |
Mankind Pharma F&O
About Mankind Pharma
- NSE Symbol
- MANKIND
- BSE Symbol
- 543904
- ISIN
- INE634S01028
Similar Stocks to Mankind Pharma
Mankind Pharma FAQs
Mankind Pharma share price is ₹2,325 As on 19 June, 2025 | 23:37
The Market Cap of Mankind Pharma is ₹95967.7 Cr As on 19 June, 2025 | 23:37
The P/E ratio of Mankind Pharma is 48.2 As on 19 June, 2025 | 23:37
The PB ratio of Mankind Pharma is 9.1 As on 19 June, 2025 | 23:37
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.